A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Name: A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Creator: Vivli
Published: 2024-05-28T10:19:03+08:00

DataCite Commons2025-02-10 更新2026-05-07 收录

血液肿瘤治疗

淋巴瘤临床试验

数据链接：

https://search.vivli.org/doiLanding/studies/PR00010129/isLanding 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

提供机构：

Vivli

创建时间：

2024-05-28